Kraig Biocraft Laboratories’ Research Team Readies Next Breakthrough in Recombinant Spider Silk Performance

ANN ARBOR, Mich., – December 9, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its research and development (“R&D”) team has expanded their research focus far beyond the spider silk proteins in the Company’s Monster Silk® and Dragon SilkTM products.  These new protein designs have the potential to create new materials and open additional markets for the Company’s recombinant silk technologies.

With the additional research personal hired this year, the Company has been able to expand its R&D into new and exciting arenas. The lab team has recently identified innovative native protein sequences from an exotic species that has demonstrated performance beyond the capabilities of the Company’s current transgenics.

The DNA encoding, from specific portions of this species’ proteins, have been synthesized and are already in the Company’s labs. These proteins are believed to be responsible for the amazing performance that the native materials exhibit.

The R&D team employed its new “mix and match” assembly system, which allows for accelerated development and performance experimentation, to design the new DNA domains to integrate with the Company’s existing DNA constructs. This approach allows the Company to produce a fiber containing a blend of current technologies with new DNA constructs to form an array of new tailored materials.

“I am very excited by the possibilities these new DNA constructs can offer.  By incorporating these new designs with our proven ‘mix and match’ assembly system, we are opening new doors and a vast array of end material properties.” said Chief Scientist, Trevor Kane, Ph.D. “I applaud my team for the willingness and determination to continually expand the cutting edge of transgenic spider silk research.”

The Company believes that these new DNA constructs should enhance future transgenic silkworm capabilities, as the isolated DNA, in these new proteins, exhibit higher performance than the Company’s original baseline transgenic spider silk proteins.

While the Company’s R&D team continues to push the boundaries of scientific possibilities, the Company will continue to advance the commercialization of its current suite of technologies, which have different target markets. In fact, the Company’s production arm, Prodigy Textiles, is preparing to make its first commercial delivery of enhanced fibers in the first quarter of 2020.  In support of this phase, the Company’s COO will be travelling to Prodigy Textiles to oversee this exciting evolutionary step in its journey to commercialize and deliver spider silk on a global scale.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Completes Hatching Second Generation of Silkworms

Rapid Expansion of recombinant Spider Silk production on track to grow Operations and yield Fibers for first significant fabric production run

ANN ARBOR, Mich., – December 3, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that Prodigy Textiles, the Company’s Vietnamese subsidiary, has completed hatching the second generation of silkworms, as it continues to expand production at its factory in Quang Nam province.  This second generation is several hundred times larger than the first generation.  The resulting cocoons from this production cycle will be used to fulfill the first commercial shipments from this new factory.  

With hatching complete, the Prodigy Textiles team is now busy rearing this significantly expanded silkworm population.  The Company anticipates these silkworms becoming cocoons over the next two weeks, with this batch of specialized silk expected to be completed by Christmas.  This cycle represents the largest single month’s production of recombinant spider silk in the Company’s history.  The Company expects this record to be quickly broken, as it continues to expand its Vietnamese operations, heading into 2020.    

The Company will be sending its COO, Jon Rice, to Vietnam to oversee the completion of this second generation.   During this trip Rice will work with the Prodigy team, as it prepares to convert the resulting cocoons into finished silk yarn.  Rice will also set the stage for further expansion with the next production cycle slated to begin in early January. 

 “The smooth transition from our first production batch to this much larger second generation is a testament to the quality of the great team we have put together in Vietnam,” said Rice.  “I look forward to working hand in hand with them, later this month, to plan out the next phase of our rapid growth and to implement additional processes to support our expanding operations.”

“The pace of our production scale up is exceeding even my expectations,” said CEO and Founder, Kim Thompson.  “We’ve always believed that once we launched production in Vietnam that our growth would be rapid. Today’s announcement that we have begun the second production cycle is another in a series of exciting milestones for spider silk commercialization and Kraig Labs.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Chairman and CEO Letter to Shareholders

ANN ARBOR, Mich., – Nov 26, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”) (“Kraig Labs”), the leading developer of spider silk based fibers, announced today the following letter to our shareholders from Kim Thompson, the Company’s Chairman, CEO, and founder.

Dear Kraig Biocraft Laboratories shareholders,

Our goal has always been to develop and produce the best spider silk based fibers.  Our suite of technological innovations has positioned Kraig Biocraft Laboratories to remain firmly in the leadership role. 2019 brought us the beginning of production operations, perhaps the most significant milestone in the Company’s work to commercialize spider silk since the creation of the first transgenics.

This year, Kraig Biocraft Laboratories officially transitioned into the increased production and scalability phase of our operations.  This operational focus will serve as the foundation in creating and maintaining long-term shareholder value. We are preparing to expand our footprint and deliver our largest ever commercial production of spider silk. 

In the coming months the Company will be delivering the first shipment of finished silk from the factory in Vietnam.  Simultaneously we are continuing to expand our production capacity.  With these developments, we are now preparing to fulfill material deliveries to numerous end markets that we are targeting for growth in 2020.

With our focus on the advancement of commercialization activities, we have determined that this is the time to elevate the Company from the OTC Markets Venture Exchange to a national exchange.  Our efforts to uplist to a national exchange are well underway, with several key pieces of this process complete.  We have elected four new board members, who stand ready to take their positions to fulfill governance requirements of the national exchanges.  We held our annual shareholder meeting and gained shareholder approval for our move to uplist. 

Securing expansion capital and listing on a national exchange will immediately impact the Company. This capital will address national exchange listing requirements and serve to underpin the Company’s work to rapidly expand capacity, build the inventory to grow our business, bring new products to market, and establish sales channel partnerships. This growth will benefit all of our shareholders.    

During the past 12 months our research team has been working quietly to deliver breakthroughs in technologies and new products in the lab.  Accelerating our development time cycle with the addition of new personnel and processes has delivered technologies and transgenics which I believe will take us far beyond Dragon Silk.  This year the Company continued to expand its intellectual property portfolio by filing the first five of many expected provisional patent applications.  We are also vigorously prosecuting the patent applications previously filed in conjunction with the University of Notre Dame.

We have shown tremendous growth in 2019 by hitting nearly every mark in our business plan.  That growth includes; obtaining approvals to commence rearing operations in Vietnam, completing the buildout of our factory in Vietnam, the initial scale up of our overseas production operations, advancements in our R&D and IP portfolio, strengthening our corporate governance in preparations for bigger things, and growth of our market cap by more than 285%. 

Our corporate developments over the last year have given us lots of reasons to be thankful.

Kraig Labs is now preparing to take a giant leap that will enhance our global presence.  Our management has been working hard over the last quarter to prepare for that leap and we believe those efforts will lead to even greater successes in 2020.  We intend to use our new position as a launching pad.

While I am thrilled over our progress and growth in 2019, this is only the foundation upon which we intend to build.  Our new assignment is to deliver spider silk to end customers and bring everything to fruition in 2020.

As we enter the holiday season I would like to express my personal appreciation to our shareholders.  We are thinking of their long term interests with every corporate decision we make.  I would also like to thank our exceptional teams at Kraig Labs and Prodigy Textiles.  I have great appreciation for the Kraig Labs family, including our outside contractors.

Thank you all for your support, and I wish you and your loved ones a Happy Thanksgiving and a blessed holiday.

Sincerely,

Kim Thompson

CEO, Chairman, and founder of Kraig Biocraft Laboratories, Inc.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Completes Scale Up Production Cycle of Recombinant Spider Silk Silkworms

ANN ARBOR, Mich., – November 18, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that Prodigy Textiles, the Company’s Vietnamese subsidiary, completed the first cycle of silk moth mating and egg production scale up, at the Quang Nam factory. 

The Prodigy Textiles operations team finished removing the cocoons from mounting frames on November 6th and silk moths began emerging by November 9th.  The breeding of the emerged moths is complete, with the specialized silkworm eggs now in incubation and are expected to emerge shortly. Each female silk moth lays upwards of 200-500 eggs and, as previously announced, all of the emerged silk moths were dedicated to breeding stock expansion to rapidly scale up the Company’s silk production capacity. 

Over the coming weeks, the Company expects to hatch and rear this second round of silkworms, then harvest the resulting cocoons for production of the first recombinant spider silk threads manufactured in Vietnam.  The Company will contract with a nearby reeling facility to convert the cocoons into finished silk yarn, which has already been committed to a textile manufacture for further fabric and product development.

The Company plans to continue to expand its throughput, over the next several quarters, as it builds up its capacity, expand operations, and prepares to ship materials to its collaborators and potential customers. 

“The launch of each new production phase marks a significant Prodigy milestone, so this is an especially exciting time for Kraig Labs, which, after the years and efforts needed to overcome numerous challenges and regulatory hurdles, is successfully transitioning our technology from the lab to the factory,” said COO, Jon Rice. “It is a pleasure to share each meaningful step forward and, over the next few quarters, we anticipate some thrilling changes for our business and our shareholders, as we begin bringing our recombinant spider silk technologies and capabilities to the markets.” 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Completes Rearing of First Production Batch of Recombinant Spider Silk Silkworm in Vietnam Factory

ANN ARBOR, Mich., – November 4, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its operations team at its Vietnamese subsidiary, Prodigy Textiles, has completed rearing the Company’s first batch of production silkworms.  The Company’s specialized spider silk silkworms were hatched over a 7 day period starting on October 8th, while Jon Rice, the Company’s COO, was in Vietnam.  The silkworms began spinning cocoons on October 27th and finished on November 2nd

The Company is already in the process of removing the finished cocoons from the mounting frames, which will be complete by November 6th.  Upon completion, the cocoons will be prepared for the silk moths to emerge.  As reported, late last month, the entire population of emerging silk moths will be dedicated to breeding stock, in order to rapidly expand the Company silk production capacity at Prodigy Textiles.

The second round of production is slated to begin later this month and the resulting silk cocoons will be reeled and spun into finished silk thread.  This thread will be the first recombinant spider silk thread available from Prodigy Textiles and is scheduled to be delivered to a collaborative partner the Company has been working with to develop new materials and applications. 

With operations now fully underway, the Company expects to maintain a continuous production output at Prodigy Textiles and will plan to bring additional materials to market to address the backlog of inquiries in the coming months. 

“The Prodigy Textiles production ramp up continues to demonstrate the efficacy of our manufacturing strategy. The success of this first wave of operations will serve as the blueprint for the successive expansion.  Our direct, drop-in strategy is already proving its effectiveness to scale Dragonsilk 2.0.   We believe this demonstration of rapid expansion will clear the path to fast-track our operations growth and quickly reach our targeted capacity,” Rice said.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Spider Silk Facility to Break Corporate Production capacity Records within First Months of Operation

ANN ARBOR, Mich., – Oct 28, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that operations at its Vietnamese production facility, which just formally kicked off earlier this month, are on track to set new production capacity records for the Company.

As expected, the first batch of production silkworms, announced earlier this month, are thriving on their diet of fresh mulberry leaves and the warm, humid climate at the facility in Vietnam. 

The Company expects that this first round of production will be complete within two to three weeks.  The entire population of emerging silk moths, from this first production cycle, will be dedicated to breedstock population expansion, resulting in a more than a 100x increase in silkworm egg production and preparing for what the Company believes will be its largest production batch, scheduled for November. 

The November production batch, in Vietnam, is expected to expand the Company’s capacity to produce its specialized recombinant spider silk to a level that collectively exceeds the entirety of its U.S based production, over the last ten years. 

This critical milestone, in the Company’s commercialization of eco-friendly and cost effective recombinant spider silk, has been the key focus of Company management’s initiative to create high performance and environmentally sustainable alternatives to synthetic textiles. The completion of this first wave of production is validating the Company’s business model and its transgenic spider silk silkworms. The Company expects that its factory will have capacity to produce more than 8 metric tons of its specialized silk in 2020, with a total capacity of roughly 40 metric tons per year, once fully utilized.

“There has been considerable interest in Kraig Labs’ high performance fibers, from multiple internationally recognized brands, so bringing our specialized silkworms online should allow us to deliver our first large batch of fabric and begin to fulfill the fiber request backlog,” said COO Jon Rice.  “Having now successfully delivered the silkworms to the factory, watched our team hard at work rearing this first batch, and preparing the factory for the expanding workload, and walked the rows of silk production rack, tray, and mounting boxes, I believe that we are on track to meet our production targets for 2020.”  

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Confirms Selection of Jon Rice as a New Inside Director for its Board of Directors

ANN ARBOR, Mich., – October 23, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has selected Jon Rice, the Company’s COO, to join its Board of Directors, as the Company advances and strengthens its corporate governance.

Rice has served as the COO of Kraig Biocraft Laboratories since 2015.  In this role, Rice has overseen and led operations at the Company’s domestic research and development headquarters as well as the recent breakthroughs in the scale-up of its international production operations, through its subsidiary, Prodigy Textiles Co., Ltd.  Prior to joining Kraig Labs, Rice served in a series of leadership roles developing and marketing advanced power systems, developed under contract with the US Department of Defense, which were successfully leveraged into commercial spinoff products.  Rice blends technical and business operations expertise, holding a degree in both engineering and a master’s in business administration.

“We are pleased to welcome Jon, with his first hand working knowledge and experience of implementing our operations, to the Kraig Labs board,” said chairman and CEO, Kim Thompson.  “Jon’s role and understanding of our Company, from the inside, will serve as a crucial bridge between day to day operational management and board governance.

The addition of Rice to the board will strengthen the overall skill set, perspective, and experience necessary to support and drive growth for all of the Company’s stakeholders.  Rice’s understanding of Kraig’s operations will provide a strong link to the board’s fiduciary oversight responsibilities.

Rice’s term is expected to begin this quarter.

Once formally seated, Rice, and the three recently announced new independent directors, will join Thompson to form the majority independent controlled board, which is intended to satisfy the uplisting requirement of a national exchange.

“I am excited for the opportunity to expand my service to Kraig Labs and our Shareholders in this new role, said Rice.  “The advancement we are making in all aspects of our business model, from research to governance and commercialization, make this a fantastic time to be part of Kraig Labs and our exciting growth.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Launches Spider Silk Production Scale up with New Delivery of Silkworms to Prodigy Textiles

ANN ARBOR, Mich., – Oct 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, is very happy to announce today that the Company has officially initiated commercial production scale up of its recombinant spider silk production at its Vietnamese subsidiary, Prodigy Textiles.  During a trip this week Jon Rice, the Company’s chief operating officer, successfully delivered the Company’s specialized silkworm eggs to the production team, at Prodigy Textiles’ recently renovated factory.  This moment marks a pivotal milestone in the commercialization and production of eco-friendly and cost effective recombinant spider silk. 

“The significance of today’s announcement can’t be overstated.  By clearing this critical production hurdle, we are now aggressively ramping up to produce and fill demand for our recombinant spider silk materials,” said Rice. “Having demonstrated our materials’ performance capabilities and secured necessary approvals, we are now focused on the exciting next phase of our business model; delivering our high performance silk yarns to the market and formalizing strategic partnerships.  Our dream of a sustainable and cost effective method to produce recombinant spider silk is now in operation.”

With capacity scale up now officially underway in Vietnam, the Company is focused on the production of its recombinant spider silk threads and yarns for delivery to collaborative partners and target market segments.

The Company has been working with senior officials in Vietnam for several years to secure the necessary permits and approvals needed to bring its revolutionary spider silk technology to production.  The delivery of these progenitor silkworms into the Company’s Vietnamese facility marks the success of that process and the beginning of a new era in performance textiles. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories COO Travels to Vietnam to Assist Transition of Production Operations to New Factory

ANN ARBOR, Mich., – October 2, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that Jon Rice, the Company’s chief operating officer, will travel to Vietnam, this week, to work with the Company’s subsidiary, Prodigy Textiles, on the transition of silk production operations into its recently renovated facility in Quang Nam province.  During this trip, Rice expects to review the completed facility improvements, coordinate operations with Prodigy Textiles senior staff and production workers, finalize production and transportation logistics, discuss production throughput rates and targets, as well as review the security and quality control systems being implemented. 

 “Our staff, in the U.S. and Vietnam, has put an incredible amount of effort into establishing and preparing Prodigy Textiles to disrupt the performance textile markets.  Our team has pushed through incredible challenges to bring this factory online.  We are now ready to put it to work, bringing our recombinant spider silk technology to market.  I expect to be able to share more information about my trip and details about our operations with our shareholders early next week,” said Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Completes Selection of Independent Directors for its Board of Directors

ANN ARBOR, Mich., – Sept 25, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that, with the appointment of Mr. Greg Scheessele, as the third and final independent Board member, it has completed the selection of independent members for its Board of Directors.

Mr. Scheessele currently serves as the CEO of Gerette, LLC and has held several top executive roles in global manufacturing firms including: Executive Vice President, TMD Americas at TMD Friction Holdings GmbH; Group Vice President, Global Operations at Pall Corporation and Gelman Sciences; and Manufacturing Manager at General Motors Powertrain Division.  Mr. Scheessele has served on various corporate and non-profit boards over the past twelve years.

Over the last two weeks the Company announced the selections of three new independent directors scheduled to join the Company’s board during the fourth quarter, including Mr. Anurag Gupta, Ms. Julie Bishop, and Mr. Greg Scheessele.  The Company anticipates selecting one additional inside director to round out its board.

“We are pleased to welcome Greg to the Kraig Lab’s board in the role of an independent director,” said chairman and CEO, Kim Thompson.  “Greg’s background, experience, and leadership focused in businesses with global operations in manufacturing, industrial and life sciences sectors will be a tremendous asset to our corporate strategy as we continue on our growth trajectory.  With this announcement, the Company has reached a new and important milestone in its corporate governance, advancing our business model.”

The addition of Mr. Scheessele to the board will expand the overall skillset, perspective and experience necessary to support and drive growth for all of the Company’s stakeholders.  Mr. Scheessele has a strong history of leading successful business operations on a global scale.

Mr. Scheessele’s term will begin during the fourth quarter and he will serve on the audit and compensation committees for the duration of his time as a director.

Once these three new independent directors are formally seated, during the fourth quarter, the Company will be governed by a majority of independent directors, which is a key requirement for listing on a national exchange.

“I am very excited to join the Kraig Biocraft Laboratories board,” said Mr. Scheessele.  “I look forward to supporting Kim Thompson and his team with their exciting work focusing on the development and commercialization of spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .